Introduction
============

The esophagus is the main site of extrapulmonary small cell carcinoma, and primary small cell esophageal carcinoma (SCEC) represents 1.0% to 2.8% of all esophageal cancers.[@b1-ott-8-437],[@b2-ott-8-437] The incidence of SCEC is highest in Southeast Asian countries, including Japan, Korea, and the People's Republic of China.[@b3-ott-8-437],[@b4-ott-8-437] SCEC is similar to small cell lung cancer (SCLC) in that both have a high frequency of regional and distant spread at time of diagnosis and a poor overall prognosis.[@b5-ott-8-437],[@b6-ott-8-437]

The term "combined SCEC" (C-SCEC) is defined by World Health Organization (WHO) as SCEC with an additional component of non--small cell carcinoma, including squamous cell carcinoma, adenocarcinoma, or other carcinoma. Limited-stage (LS) C-SCEC (LS-C-SCEC) is currently considered a subset of SCEC, although biologic evidence to support this classification scheme is lacking. An accurate understanding of LS-C-SCEC is of great practical importance; its optimal treatment strategy may be different than that of pure SCEC,[@b4-ott-8-437],[@b7-ott-8-437]--[@b9-ott-8-437] neuroendocrine esophageal carcinoma,[@b10-ott-8-437] or non-SCEC,[@b11-ott-8-437] akin to pure SCLC and combined SCLC (C-SCLC).[@b12-ott-8-437],[@b13-ott-8-437]

Evidence behind the optimal therapeutic approaches to LS-C-SCEC is limited because of (1) the infrequency of the disease; (2) various treatment strategies (including surgery \[S\], chemotherapy \[CT\], radiotherapy \[RT\], and combinations of these treatments) have been reported to have similar outcomes;[@b4-ott-8-437] and (3) the prognosis for pure SCEC and C-SCEC is reportedly similar.[@b4-ott-8-437] Our previous study demonstrated that patients with pure LS-SCEC treated with RT+CT had an improved survival compared with those treated with S+CT.[@b8-ott-8-437] We believe LS-C-SCEC is a unique disease, and its optimal management may be different than that of LS-SCEC. Therefore, we performed a retrospective study to evaluate the clinical features, optimal treatment strategy, and prognostic factors in patients with LS-C-SCEC.

Patients and methods
====================

Study design and patient eligibility
------------------------------------

Eligible patients with LS-C-SCEC were recruited from our hospital and the literature.[@b2-ott-8-437],[@b5-ott-8-437],[@b9-ott-8-437],[@b14-ott-8-437]--[@b31-ott-8-437] The inclusion criteria were: (1) a pathological diagnosis of primary LS-C-SCEC; (2) treatment, including S, RT, CT, or a combination of these; and (3) a report of overall survival (OS) time. The exclusion criteria for patients were as follows: (1) a diagnosis of pure esophageal carcinomas (eg, squamous cell carcinoma, adenocarcinoma, or small cell carcinoma); (2) a diagnosis of extensive stage C-SCEC; (3) uncontrolled comorbid conditions (metabolic or psychiatric); and (4) an unreported OS time. The study protocol was in accordance with the ethical guidelines of the 1995 Declaration of Helsinki and was approved by independent ethics committees at Tianjin Medical University Cancer Institute and Hospital.

Literature search strategy and data extraction
----------------------------------------------

We searched MEDLINE for patients treated for SCEC between January 1966 and December 2013. A preliminary search was designed to find all articles including the terms "small cell carcinoma" or "oat cell carcinoma" combined with "esophagus" or "esophageal." Three reviewers independently selected the patients and performed the data extraction, from these articles and their references. Discrepancies regarding stated information in articles were resolved by discussion among reviewers. All principal investigators who initially included these patients were contacted using the corresponding e-mail addresses listed in the respective studies. The message sent to the authors both acknowledged their original work and asked for permission to include their patients in the current study. Of the authors without functioning addresses, none objected to having his/her patients included in the current study. Further, principal investigators were asked to supplement information that was missing from the original publication.

Treatment schedule
------------------

S was defined as radical resection of the primary tumor and/or local lymphadenectomy. RT was administered with conventional fields (two anterior--posterior opposed fields and two anterior--posterior \[AP-PA\] oblique opposed fields), three-dimensional (3D) conformal radiotherapy (3D-CRT), or intensity-modulated radiotherapy (IMRT). Data gathered about CT included agent(s) used and number of CT cycles.

Outcome measurements and end points
-----------------------------------

The primary outcome was OS. Secondary outcomes included tumor response rate (complete response \[CR\] and partial response \[PR\], clinically assessed at the time of follow up), pattern of failure (eg, locoregional recurrence \[LRR\] and distant metastasis \[DM\]), and treatment toxicity. OS was defined as the time between date of pathological diagnosis and date of death. The patients taken from literature who were alive at the reported time of communication were coded as being lost to follow up.

Statistical analysis
--------------------

A *χ*^2^ test or Fisher's exact test were performed for qualitative data. OS curves were estimated by using the Kaplan--Meier technique and compared using the stratified log-rank test. Univariate analysis (UVA) and multivariate analysis (MVA) were performed using a Cox regression model. Predictors analyzed included sex, age (≤60 vs \>60 years), tumor location (upper vs middle vs lower third), tumor size (≤5 vs \>5 cm), combined additional components (squamous cell carcinoma vs adenocarcinoma vs others, and their combinations), the number of additional histological components (one vs two or more), CT regimen (platinum- vs non-platinum-based), and type of treatment (monotherapy vs combination therapy). Data were analyzed using Intercooled Stata, version 8.2 for Windows (Stata Corp, College station, TX, USA), with a *P*-value of \<0.05 considered significant.

Results
=======

Patient characteristics
-----------------------

A total of 72 patients were included in the analysis: 24 patients (33%) from our hospital and 48 patients (67%) from 21 publications.[@b2-ott-8-437],[@b5-ott-8-437],[@b9-ott-8-437],[@b14-ott-8-437]--[@b31-ott-8-437] The baseline characteristics of all patients are shown in [Table 1](#t1-ott-8-437){ref-type="table"}. The characteristics of patients from our institution are summarized in [Table 2](#t2-ott-8-437){ref-type="table"}. Among the 17 patients who underwent monotherapy, 13 (18%) were treated with S, two (3%) with CT, and two (3%) with RT. A total of 55 patients underwent multimodality therapy, including 13 (18%) patients who received CT+RT, 29 (40%) who received S+CT, one (1%) who received S+RT, and 12 (17%) who received S+CT+RT.

Overall survival
----------------

All patients were followed until death or December 2013. The median follow-up time was 15.0 (range 3--108) months. For the whole cohort, the median OS was 15.0 months; the 1-year, 2-year, and 3-year OS rates were 56%, 39%, and 27%, respectively ([Figure 1A](#f1-ott-8-437){ref-type="fig"}). Compared with patients without CT, patients with CT had significantly improved median OS (10.0 months vs 22.8 months) (*P*=0.03) ([Figure 1B](#f1-ott-8-437){ref-type="fig"}). Patients who received multimodality therapy (eg, RT+CT, S+CT, S+RT, or S+RT+CT) had significantly improved OS compared with those who received monotherapy with any technique (15.5 months vs 9.3 months) (*P*=0.02) ([Figure 1C](#f1-ott-8-437){ref-type="fig"}). The survival time showed a slight trend towards superiority of S+CT+RT over CT+RT or S+CT, although these differences were not statistically significant because of the small sample (*P*=0.73) ([Figure 1D](#f1-ott-8-437){ref-type="fig"}).

Tumor response and patterns of failure
--------------------------------------

There were 56 patients had reported tumor response. A total 19 (19/56 \[34%\]) and 37 patients (37/56 \[66%\]) had a CR and PR, respectively. Among the 19 patients with CR, the treatment modality was S alone (1/19 \[5%\]), CT+RT (1/19 \[5%\]), S+CT (12/19 \[63%\]), and S+CT+RT (5/19 \[27%\]). Among the 37 patients with PR, the treatment modality was S alone (11/37 \[30%\]), CT+RT (2/37 \[5%\]), S+CT (19/37 \[51%\]), RT (1/37 \[3%\]), and S+CT+RT (4/37 \[11%\]).

A total 25 patients (25/72 \[35%\]) had reported patterns of failure: LRR without DM (8/44 \[18%\]); DM without LRR (12/44 \[27%\]); or LRR and DM (5/44 \[11%\]). Of the 17 patients who had DM, the most frequent sites were liver (6/17 \[35%\]), lung (3/17 \[18%\]), lymph nodes (3/17 \[18%\]), bone (2/17 \[12%\]), brain (1/17 \[6%\]), and diffuse metastasis (2/17 \[12%\]).

Prognostic factors
------------------

Patient clinical characteristics were evaluated to determine their prognostic value in terms of OS. UVA indicated that sex, age, tumor size, tumor/nodes/metastasis (TNM) classification stage, types of histological components, number of histological components, and CT type were not associated with OS ([Table 2](#t2-ott-8-437){ref-type="table"}). UVA and MVA revealed that tumor location (upper third of the esophagus) and type of treatment (ie, monotherapy) were associated with worse OS ([Tables 3](#t3-ott-8-437){ref-type="table"} and [4](#t4-ott-8-437){ref-type="table"}).

Adverse events
--------------

Of all patients, only five (5/72 \[7%\]) patients had a reported adverse event secondary to treatment. All toxicities were minor (Radiation Therapy Oncology Group \[RTOG\] grade ≤2) and included esophagitis, leukopenia, anemia, thrombocytopenia, and bone marrow suppression. And these toxicities were resolved with routine treatment.

Discussion
==========

LS-C-SCEC is a rare subtype of SCEC. The optimal treatment strategy for LS-C-SCEC is controversial. Previous studies have suggested that pure LS-SCEC and LS-C-SCEC have similar behavior and outcomes, perhaps independent of treatment.[@b4-ott-8-437],[@b32-ott-8-437] However, most of these reports are relatively small retrospective series, and LS-C-SCEC has been included as a subset of patients with LS-SCEC. The current retrospective study demonstrated that LS-C-SCEC should be treated as a unique disease entity. Moreover, LS-C-SCEC patients who received multimodality therapy (which included CT) have significantly improved OS compared with patients receiving monotherapy.

Generally, the size of biopsy and presence of crush artifact, as well as number of study specimens taken by routine biopsy contribute to the underdiagnosis of C-SCEC.[@b4-ott-8-437],[@b33-ott-8-437] In addition, change in histology during the treatment period also makes the diagnosis more challenging,[@b34-ott-8-437] akin to C-SCLC.[@b35-ott-8-437] In this study, the vast majority (55/72 \[76%\]) of patients were diagnosed by postoperative pathology, which illustrates the importance of histopathological diagnosis. Therefore, it is postulated that the incidence of C-SCEC may be underestimated. In this study, the most frequent histological component was squamous cell carcinoma, in agreement with a previous report.[@b36-ott-8-437] The coexistence of pure SCEC with squamous cell carcinoma or other histologies in the same lesion is supported by the hypothesis that SCEC originates from amine precursor uptake and decarboxylation (APUD) cells or pluripotent stem cells.[@b37-ott-8-437]

We believe that the rarity of LS-C-SCEC is the primary reason that there is a lack of consensus regarding its optimal treatment. From a clinical standpoint, our data indicate that LS-C-SCEC has historically been treated similar to non-SCEC, in that S has been an integral treatment approach for LS-C-SCEC (76% of cases) and LS-SCEC.[@b8-ott-8-437] Additionally, we note that patients with pure LS-SCEC have significantly improved OS compared with LS-C-SCEC.[@b8-ott-8-437] The reason for this OS discrepancy is unclear and may be attributed to the fact that small cell carcinoma is typically more radiosensitive than non-SCEC or that the presence of a combined histology is secondary to multiple tumor cell lines.

Compared with LS-C-SCEC patients treated without CT, our results suggest that patients treated with CT have a significantly improved OS. We believe CT is a necessary treatment for both pure SCEC and C-SCEC, akin to patients with SCLC and C-SCLC. In addition, our study demonstrated that multimodality therapy (which includes CT) is associated with improved OS versus monotherapy. The survival time showed a slight trend towards the superiority of S+CT+RT over CT+RT or S+CT, although these differences were not statistically significant because of fewer samples. Previous studies were consistent with our results, although these studies did not strictly focus on C-SCEC compared with other histologies.[@b10-ott-8-437],[@b11-ott-8-437],[@b38-ott-8-437]

RT is important in the treatment of small cell carcinoma and non--small cell carcinoma of other disease sites. In this study, a total of 28 patients (28/72 \[39%\]) received RT, either alone or in combination with S or CT. The indications and contraindications for RT (particularly as trimodality therapy with S and CT) in LS-C-SCEC should be evaluated in future prospective works.

Differences between pure SCEC and C-SCEC in terms of disease biology and pattern of metastatic spread constitute the subject of ongoing debate, and it is hypothesized that the C-SCEC has diverse biological characteristics that may influence tumor aggressiveness and treatment sensitivity. Our previous study demonstrated that the CRs were more likely to be seen in patients with pure SCEC who received RT+CT (100%) vs S+CT (88%);[@b8-ott-8-437] in the current work, CRs were more likely to be seen in patients who received CT in combination with other treatment (18/19 \[95%\]), but not RT and/or S (1/19 \[5%\]). CT appears to be an important treatment modality for both pure SCEC and C-SCEC, as evidenced by rates of CR and OS.

Interestingly, there was a significant difference in the pattern of failure (ie, LRR and DM) between pure patients with LS-SCEC (LRR and DM \[76%\]) and LS-C-SCEC (LRR and DM \[35%\]). The incidence of brain metastasis appears to be low in either disease; thus, prophylactic brain irradiation for LS-C-SCEC appears unnecessary.

Previous works have shown that the adverse prognostic factors for SCEC are advanced stage of the disease, tumor location, patient's performance status, and treatment type.[@b2-ott-8-437],[@b5-ott-8-437],[@b9-ott-8-437],[@b14-ott-8-437]--[@b31-ott-8-437] In the present study, UVA and MVA identified two independent negative prognostic factors of LS-C-SCEC: tumor location (upper third of the esophagus) and type of treatment (monotherapy, which was typically, S). Additionally, although previous reports have identified the number of histological components to be predictive of outcome in C-SCLC,[@b12-ott-8-437],[@b13-ott-8-437],[@b39-ott-8-437] the present study did not identify histology (either count or subtype) as a predictor of outcome for LS-C-SCEC.

This study has potential weaknesses. First, it is retrospective and based largely on records kept by many institutions, which may have been heterogeneous in their diagnosis and management of patients. Second, the sample size of the present study may not have been optimal; however, LS-C-SCEC is a rare and likely underdiagnosed disease of patients, particularly during the past few decades when the patients were treated. Third, CT, RT, and S have differed widely and have evolved. Finally, some patient data were missing, and with a relatively small number of patients overall, we are unable to discuss the benefit of certain treatments (eg, concurrent vs sequential CT, or salvage therapy).

In conclusion, this study indicates that LS-C-SCEC is a unique disease that should be diagnosed and managed as an entity separate from LS-SCEC. Compared with monotherapy, multimodality therapy (which includes CT) is associated with improved OS for patients with LS-C-SCEC. We recommend that S+CT+RT, S+CT, or CT+RT should be considered as possible treatment approaches for LS-C-SCEC patients.
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![OS of patients with LS-C-SCEC.\
**Notes:** (**A**) OS of all patients; (**B**) OS of patients with or without CT; (**C**) OS of patients who received monotherapy or multimodality therapy; and (**D**) OS of patients who received CT+RT, S+CT, or S+CT+RT.\
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###### 

Patient characteristics

                                                                                           n (%)
  ---------------------------------------------------------------------------------------- ---------
  Sex (72 available)                                                                       
   Male                                                                                    56 (78)
   Female                                                                                  16 (22)
  Age (years) (72 available)                                                               
   ≤60                                                                                     25 (35)
   \>60                                                                                    47 (65)
  Tumor location (55 available)                                                            
   Upper 1/3                                                                               4 (7)
   Middle 1/3                                                                              42 (76)
   Lower 1/3                                                                               9 (17)
  Tumor size (42 available)                                                                
   ≤5 cm                                                                                   29 (69)
   \>5 cm                                                                                  13 (31)
  Combined additional components (72 available)[+](#tfn1-ott-8-437){ref-type="table-fn"}   
   Squamous cell carcinoma                                                                 53 (74)
   Adenocarcinoma                                                                          6 (8)
   Squamous cell carcinoma and adenocarcinoma                                              1 (1)
   Others[‡](#tfn2-ott-8-437){ref-type="table-fn"}                                         10 (14)
   Unknown                                                                                 2 (3)
  The number of additional components (72 available)                                       
   1                                                                                       64 (89)
   ≥2                                                                                      6 (8)
   Unknown                                                                                 2 (3)
  T classification (72 available)[§](#tfn3-ott-8-437){ref-type="table-fn"}                 
   cT1                                                                                     12 (17)
   cT2                                                                                     13 (18)
   cT3                                                                                     23 (32)
   cT4                                                                                     1 (1)
   Unknown                                                                                 23 (32)
  N status (72 available)[§](#tfn3-ott-8-437){ref-type="table-fn"}                         
   cN0                                                                                     34 (47)
   cN1                                                                                     25 (35)
   Unknown                                                                                 13 (18)
  TNM stage (72 available)[§](#tfn3-ott-8-437){ref-type="table-fn"}                        
   cI                                                                                      8 (11)
   cIIa                                                                                    15 (21)
   cIIb                                                                                    11 (15)
   cIII                                                                                    17 (24)
   Unknown                                                                                 21 (29)
  Treatment types (72 available)                                                           
   S                                                                                       13 (18)
   CT                                                                                      2 (3)
   RT                                                                                      2 (3)
   CT+RT                                                                                   13 (18)
   S+CT                                                                                    29 (40)
   S+RT                                                                                    1 (1)
   S+CT+RT                                                                                 12 (17)
  CT regimen (72 available)                                                                
   Platinum-based[\*](#tfn4-ott-8-437){ref-type="table-fn"}                                49 (68)
    EP                                                                                     15 (21)
    CE                                                                                     20 (28)
    IP                                                                                     4 (6)
    PF                                                                                     10 (13)
   Non-platinum-based                                                                      7 (10)
    None                                                                                   16 (22)
  \# of CT cycles (38 available)                                                           
   \<4                                                                                     21 (55)
   ≥4                                                                                      17 (45)

**Notes:**

Pathological diagnosis according to endoscopic biopsy or postoperative biopsy.

The other combined components included sarcomatoid, Rosette, and Paget's disease.

The AJCC (6th edition) was used for staging.

Platinum-based CT regimens included cisplatin, carboplatin, or oxaliplatin.

**Abbreviations:** AJCC, American Joint Committee on Cancer; c, clinical; CE, carboplatin + etoposide; CT, chemotherapy; EP, etoposide + cisplatin; IP, irinotecan + cisplatin; PF, cisplatin + 5-fluorouracil; RT, radiotherapy; S, surgery; TNM, tumor/nodes/metastasis.

###### 

Patient characteristics, for study patients treated at our hospital

  Patient number   Age   Sex   Location   TNM stage[+](#tfn6-ott-8-437){ref-type="table-fn"}   Pathology   Treatment course   Dose of RT   CT regimen   PFS (months)   PD site                      Treatment after recurrence   Survival time and status
  ---------------- ----- ----- ---------- ---------------------------------------------------- ----------- ------------------ ------------ ------------ -------------- ---------------------------- ---------------------------- --------------------------
  1                40    M     Middle     T3N1M0 (III)                                         SC+Sq       S+CT               --           COME         10.7           Right supraclavicular LN     CT                           12.7 (DOD)
  2                54    M     Upper      T3N1M0 (III)                                         SC+Sq       S+CT+RT            60 Gy        EP+COME      7.0            Right upper mediastinal LN   RT                           23.0 (DOD)
  3                45    M     Middle     T2N1M0 (IIB)                                         SC+Sq       S+CT               --           EC           20.0           Primary tumor site           --                           27.0 (DOD)
  4                54    M     Middle     T3N1M0 (III)                                         SC+Pa       S+CT               --           EC           6.0            Multiple mediastinal LN      --                           10.7 (DOD)
  5                70    M     Middle     T3N1M0 (III)                                         SC+Pa       S+CT               --           EC           6.3            Liver and abdominal LN       --                           10.0 (DOD)
  6                70    M     Lower      T2N1M0 (IIB)                                         SC+Pa       S+CT               --           EC           24.0           None                         --                           24.0 (DOD)
  7                65    F     Middle     T2N0M0 (IIA)                                         SC+Sq       S+CT               --           COME         80.3           None                         --                           80.3 (DOD)
  8                63    M     Middle     T3N1M0 (III)                                         SC+Sq       S                  --           --           9.3            None                         --                           9.3 (DOD)
  9                70    M     Upper      T2N0M0 (IIA)                                         SC+Sq       CT+RT              60 Gy        CAP          21.4           Liver and mediastinal LN     CT                           86.0 (DOD)
  10               73    M     Middle     T3N1M0 (III)                                         SC+Pa       CT+RT              50 Gy        EC           3.4            Bone and lung                CT+RT                        9.0 (DOD)
  11               42    M     Upper      T3N1M0 (III)                                         N/A         S+CT+RT            65 Gy        EC           10.7           None                         --                           10.7 (DOD)
  12               62    M     Middle     T2N1M0 (IIB)                                         SC+Sq       S+CT               --           EP           22.8           None                         --                           22.8 (DOD)
  13               77    F     Middle     T1N0M0 (I)                                           SC+Sq       S+CT+RT            50.4 Gy      EC           4.0            The neck and hilar LN        CT+RT                        46.2 (DOD)
  14               64    M     Lower      T2N0M0 (IIA)                                         SC+Sq       CT                 --           EC           26.5           None                         --                           26.5 (DOD)
  15               73    M     Lower      T3N1M0 (III)                                         SC+Sq       CT+RT              47.4 Gy      EC           5.4            None                         --                           5.4 (DOD)
  16               62    M     Middle     T2N1M0 (IIB)                                         SC+Sq       CT+RT              60 Gy        EC           6.0            Brain                        RT                           25.2 (DOD)
  17               61    M     Middle     T3N0M0 (IIA)                                         N/A         S+CT               --           EC           7.8            None                         --                           7.8 (DOD)
  18               58    F     Middle     T2N1M0 (IIB)                                         SC+Sq       S                  --           --           32.5           None                         --                           32.5 (Alive)
  19               67    M     Middle     T3N0M0 (IIA)                                         SC+Ad       S+CT               --           EP           35.4           None                         --                           35.4 (Alive)
  20               54    M     Middle     T3N1M0 (III)                                         SC+Ad       S+CT               --           EP           2.0            Multiple metastases          --                           4.6 (DOD)
  21               52    M     Lower      T2N0M0 (IIA)                                         SC+Sq       S+CT               --           PF           11.7           Liver and lung               CT                           15.5 (DOD)
  22               55    M     Middle     T3N0M0 (IIA)                                         SC+Sq       S+CT+RT            50 Gy        EP           24.0           Bone and LN                  RT+CT                        30.3 (DOD)
  23               71    M     Middle     T2N0M0 (IIA)                                         SC+Sq       S+CT+RT            54 Gy        PF           13.7           None                         --                           13.7 (DOD)
  24               62    F     Upper      T3N1M0 (III)                                         SC+Sq       S+CT               --           EC           4.8            None                         --                           4.8 (Alive)

**Note:**

The AJCC (6th edition) was used for staging.

**Abbreviations:** Ad, adenocarcinoma; AJCC, American Joint Committee on Cancer; CAP, cyclophosphamide + doxorubicin + cisplatin; DOD, died of disease; CT, chemotherapy; COME, cyclophosphamide + vincristine + methotrexate + etoposide; EC, etoposide + carboplatin; EP, etoposide + cisplatin; F, female; LN, lymph node; M, male; NA, not available; Pa, Paget's disease; PD, progressive disease; PF, cisplatin + 5-fluorouracil; PFS, progression-free survival; RT, radiotherapy; S, surgery; SC, small cell; Sq, squamous cell carcinoma; TNM, tumor/nodes/metastasis.

###### 

Univariate analysis of the prognostic factors for survival in patients with LS-C-SCEC

  Characteristics                                                     MST (months)   1-year OS (%)   3-year OS (%)   *χ*^2^   *P*-value
  ------------------------------------------------------------------- -------------- --------------- --------------- -------- ---------------------------------------------------
  Sex (72 available)                                                                                                          
   Female                                                             12.0           50              33              0.969    0.325
   Male                                                               13.7           57              23                       
  Age (years) (72 available)                                                                                                  
   ≤60                                                                22.8           54              27              0.041    0.839
   \>60                                                               12.7           58              25                       
  Tumor location (55 available)                                                                                               
   Upper 1/3                                                          7.0            9               0               28.84    0.0001[\*](#tfn11-ott-8-437){ref-type="table-fn"}
   Middle 1/3                                                         24.0           67              30                       
   Lower 1/3                                                          80.3           63              31                       
  Tumor size (42 available)                                                                                                   
   ≤5 cm                                                              12.0           55              25              0.345    0.557
   \>5 cm                                                             23.0           59              33                       
  TNM stage (51 available)[+](#tfn8-ott-8-437){ref-type="table-fn"}                                                           
   cI                                                                 15.0           63              38              2.325    0.508
   cIIa                                                               12.0           43              22                       
   cIIb                                                               15.0           64              27                       
   cIII                                                               11.0           45              12                       
  Combined additional components (70 available)                                                                               
   Sq                                                                 12.7           55              21              1.054    0.788
   Ad                                                                 10.7           33              17                       
   Sq+Ad                                                              27.0           --              --                       
   Others[‡](#tfn9-ott-8-437){ref-type="table-fn"}                    15.0           56              30                       
  The number of additional components (70 available)                                                                          
   1                                                                  12.7           55              21              0.742    0.389
   ≥2                                                                 27.0           60              30                       
  Type of treatment (72 available)                                                                                            
   Monotherapy                                                        8.0            23              0               30.83    0.0001[\*](#tfn11-ott-8-437){ref-type="table-fn"}
   Combination therapy                                                26.5           74              32                       
  CT type (43 available)[§](#tfn10-ott-8-437){ref-type="table-fn"}                                                            
   Platinum-based                                                     12.7           57              27              1.133    0.287
   Non-platinum-based                                                 10.0           33              0                        

**Notes:**

The AJCC (6th edition) was used for staging.

The other combined components included sarcomatoid, Rosette, and Paget's disease.

Platinum-based CT regimens included cisplatin, carboplatin, or oxaliplatin.

*P*-value \<0.05.

**Abbreviations:** Ad, adenocarcinoma; AJCC, American Joint Committee on Cancer; CT, chemotherapy; LS-C-SCEC, limited-stage combined small cell esophageal carcinoma; MST, median survival time; OS, overall survival; Sq, squamous cell carcinoma; TNM, tumor/nodes/metastasis.

###### 

Multivariate Cox regression analysis of predictors for OS in patients with LS-C-SCEC

  Characteristics                                                                                          HR      95% CI          *P*-values
  -------------------------------------------------------------------------------------------------------- ------- --------------- --------------------------------------------------
  Sex (male vs female)                                                                                     0.576   0.141--2.354    0.443
  Age (≤60 vs \>60 years)                                                                                  0.764   0.138--4.230    0.758
  Tumor size (≤5 vs \>5 cm)                                                                                0.757   0.188--3.052    0.696
  Tumor location (upper 1/3 vs middle 1/3 vs lower 1/3)                                                    0.210   0.057--0.770    0.019[\*](#tfn13-ott-8-437){ref-type="table-fn"}
  TNM stage (cI vs cIIa vs cIIb vs cIII)[+](#tfn14-ott-8-437){ref-type="table-fn"}                         1.009   0.517--1.969    0.980
  Combined additional components (Sq vs Ad vs Sq+Ad vs others)[‡](#tfn15-ott-8-437){ref-type="table-fn"}   1.094   0.549--2.180    0.798
  The number of additional components (1 vs ≥2)                                                            1.414   0.157--12.728   0.757
  Type of treatment (multimodality vs monotherapy therapy)                                                 0.063   0.005--0.731    0.027[\*](#tfn13-ott-8-437){ref-type="table-fn"}
  CT type (platinum-based vs non-platinum-based)[§](#tfn16-ott-8-437){ref-type="table-fn"}                 1.469   0.332--6.510    0.613

**Notes:**

*P*-value \<0.05.

The AJCC (6th edition) was used for staging.

The other combined components included sarcomatoid, Rosette, and Paget's disease.

Platinum-based CT regimens included cisplatin, carboplatin, or oxaliplatin.

**Abbreviations:** Ad, adenocarcinoma; AJCC, American Joint Committee on Cancer; CI, confidence interval; CT, chemotherapy; HR, hazard ratio; LS-C-SCEC, limited-stage combined small cell esophageal carcinoma; OS, overall survival; Sq, squamous cell carcinoma; TNM, tumor/nodes/metastasis.

[^1]: \*These authors contributed equally to this work
